Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edwards Lifesciences Corporation (NYSE: EW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a structural heart medical device manufacturer. These filings, sourced from the SEC’s EDGAR system, include current reports on material events, earnings announcements, capital markets activity and other items relevant to shareholders and analysts.
Edwards Lifesciences uses Form 8‑K to report developments such as quarterly financial results, financial guidance updates, leadership transitions, accelerated share repurchase agreements and legal or regulatory matters. Recent 8‑K filings, for example, describe third‑quarter financial results, a planned chief financial officer transition, an accelerated share repurchase agreement and legal proceedings related to the Federal Trade Commission’s successful motion to block the proposed acquisition of JenaValve Technology.
In addition to current reports, investors typically review Edwards’ annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide detailed information on its structural heart portfolio, risk factors, research and development spending, and segment performance across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies and surgical heart valves. Proxy statements on Schedule 14A and beneficial ownership or insider trading reports on Forms 3, 4 and 5 offer further insight into governance and executive equity activity.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language, highlight important changes from prior periods and help readers interpret complex sections. Real‑time updates ensure that new Edwards Lifesciences filings appear promptly, while AI‑generated overviews of 10‑K, 10‑Q and Form 4 documents can assist users in quickly understanding the implications of lengthy disclosures and insider transactions without replacing their own review of the original filings.
Edwards Lifesciences CVP and Chief Financial Officer Scott B. Ullem exercised employee stock options for 13,000 shares of common stock at an exercise price of $59.2567 per share and sold 13,000 shares in open-market transactions. The sales occurred in two tranches at weighted average prices of $80.4963 and $79.7866 per share under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025. After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, resulting in a net reduction of 13,000 shares in his position.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share and immediately sold 1,019 shares at a weighted average price of $80.9840 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 30, 2025, indicating they were scheduled in advance. Following the transactions, Lippis directly owns 33,933.9103 shares of Edwards Lifesciences common stock.
Edwards Lifesciences Corp corporate VP Donald E. Bobo Jr. exercised employee stock options for 22,680 shares of common stock at an exercise price of $59.2567 per share. On the same date, he sold a total of 22,680 shares in open-market transactions at weighted average prices of $80.5915 and $80.0494 per share.
After these transactions, he directly holds 21,266.2532 shares of common stock, with additional indirect holdings of shares represented in a 401(k) plan and a trust. The filing states that these trades were effected under a Rule 10b5-1 trading plan adopted on February 27, 2025.
Edwards Lifesciences Corp ownership update: The Vanguard Group filed an amendment reporting 0 shares beneficially owned and 0% of common stock as of the amendment. The filing explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries to report separately.
Edwards Lifesciences reported strong 2025 results and strategic progress across structural heart therapies. Net sales from continuing operations were $6.1B with an adjusted net sales growth rate of 10.7%. The company invested more than $1B in research and development (about 17.8% of sales) and reported a gross margin of 78%. Product milestones included regulatory approvals and evidence gains for the SAPIEN family (including an approval for asymptomatic severe aortic stenosis), U.S. and EU approvals for SAPIEN M3, favorable real-world registry outcomes for EVOQUE, and long-term durability data for RESILIA. Edwards employed ~16,000 people and reported 580.8 million shares outstanding as of January 31, 2026. The report describes forward-looking plans for expanded adoption, clinical evidence generation, and continued investment in emerging areas such as heart failure and aortic regurgitation, and includes standard forward-looking statement cautions.
Edwards Lifesciences Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 7, 2026. Holders of common stock as of March 10, 2026 can vote online, by phone, mail, or during the webcast.
Stockholders will elect nine directors for one-year terms, cast an advisory vote on named executive officer pay, ratify PricewaterhouseCoopers LLP as independent auditor for 2026, and approve an amended and restated Long-Term Stock Incentive Compensation Program. The board, led by an independent chair, recommends voting “FOR” all four proposals.
The company highlights 2025 sales of $6.1 billion, up 11.5% on an underlying basis, and more than $1 billion invested in research and development across TAVR, TMTT and Surgical therapies. Annual cash incentives funded at 127% of target, while 2022 performance-based RSUs tied to three-year relative total shareholder return did not vest. Edwards emphasizes strong governance features, including majority voting for directors, proxy access, no poison pill, robust stock ownership guidelines and an executive pay program where a high proportion of compensation is performance-based.
Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem exercised options for 13,000 shares of common stock at $59.2567 per share on March 11, 2026, then sold all 13,000 shares in open-market transactions at weighted average prices of $84.4613 and $85.2079.
After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, so the 13,000-share sale represents a small portion of his total reported holdings. All transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025, indicating they were scheduled in advance.
Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share, then sold 1,019 shares of common stock at a weighted average price of $85.3822.
These transactions were executed on March 11, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on July 30, 2025. Following the sale, Lippis directly holds 33,933.9103 shares of Edwards Lifesciences common stock, indicating he retained the vast majority of his equity position.
Edwards Lifesciences (EW) submitted a Form 144 notice relating to Common Stock with a broker identified as Charles Schwab & Co., Inc. The filing lists a transaction date of 03/11/2026 described as an Employee Stock Option Exercise with “Broker Payment for Cashless Exercise.” The filing also lists two prior entries under "Securities Sold During The Past 3 Months" for Daniel J. Lippis with dated entries 12/12/2025 and 01/09/2026 and amounts 85625.00 and 87332.00 respectively.
Edwards Lifesciences reported a Form 144 covering the proposed sale of 26,000 shares of Common Stock on 03/11/2026. The filing lists Employee Stock Option Exercise - Broker Payment for Cashless Exercise as the transaction method and identifies Charles Schwab & Co. as the broker.